Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PR 006

Next Previous
Drug Profile

PR 006

Alternative Names: GRN gene therapy - Eli Lilly and Company; LY-3884963; PR-006; PR006A

Latest Information Update: 09 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prevail Therapeutics
  • Class Antidementias; Gene therapies
  • Mechanism of Action Gene transference; Progranulin protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dementia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Frontotemporal dementia

Most Recent Events

  • 08 Feb 2022 Phase-II clinical trials in Frontotemporal dementia in USA (Intracisternal) as of February 2022 (Eli Lilly and Company pipeline, February 2022)
  • 22 Jan 2021 Prevail Therapeutics has been acquired by Eli Lilly and Company
  • 30 Nov 2020 PR 006 receives Orphan Drug status for Dementia in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top